Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dipyridamole for Post-Transplant Hypophosphatemia
NCT06824454Phase 2Recruiting
- Sponsor
- Stanford University
- Start
- May 2025
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dipyridamole in hypophosphatemia (2 arms), sponsored by Stanford University. Primary endpoint: Change in Serum Phosphorus Levels. Started May 2025; status: recruiting.
02
Drugs
dipyridamole
03
Conditions
hypophosphatemia
Beyond the preview
Go deeper on NCT06824454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06824454.